FRIDAY, JUNE 22, 2018

Alex Martin named CEO of PuriCore

Courtesy of

PuriCore last week named Alex Martin as its new chief executive officer, effective on June 18.

Martin will join the company on June 1 to begin the smooth transition after Michael Ashton, the current PuriCore CEO, retires. 

Martin attended Cornell University for his bachelor's degree and Harvard University for his master's. He speaks several languages, and has lived and worked in five countries. His experience encompasses commercial, strategic and operational duties, and he has been a leader in successfully creating and launching new products. He has negotiated large licensing arrangements, driven operational enhancements, and led IPOs and private fundraising initiatives.

Martin, whose new responsibilities will base him at PuriCore’s headquarters in Pennsylvania, has more than 25 years of experience serving in senior positions in the pharmaceutical and biopharmaceutical industry. Most recently, Martin was the president at moksha8, which is a specialty pharmaceutical company in Latin America. He previously was the CEO of Affectis Pharmaceuticals AG, the chief business officer of Bioxell S.p.A and chief operating officer of Intercept Pharmaceuticals.

"We are delighted to welcome Alex to PuriCore at an important time in the company's development,” Charles Spicer, non-executive chairman of PuriCore, said. “We are confident that with his broad operational background and leadership experience across a range of companies, he is well suited to enable us to capitalize on the opportunities identified in our strategic and operational review as well as to identify potential new ones."

Organizations in this Story

Affectis Pharmaceuticals AG Bioxell S.p.A Intercept Pharmaceuticals PuriCore, Inc.

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.